Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NAI Acne

Drug Profile

NAI Acne

Alternative Names: BI-Acne; BI-K-0376; CB-06-01; CB-06-04; NAI-003; NAI-Acne; VIC-acne

Latest Information Update: 11 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vicuron Pharmaceuticals
  • Developer Cassiopea; NAICONS
  • Class Amides; Antiacnes; Antibacterials; Peptide antibiotics; Peptides
  • Mechanism of Action Peptide elongation factor Tu inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 11 Mar 2019 NAI Acne is still in phase II trials for Acne vulgaris in Slovakia (Cassiopea website, March 2019)
  • 11 Mar 2019 Cassiopea plans a phase III trial for Acne Vulgaris in 2021-2022 (Topical) (Cassiopea pipeline, March 2019)
  • 11 Sep 2005 Vicuron Pharmaceuticals has been acquired and merged into Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top